{"product_id":"002252sz-business-model-canvas","title":"Shanghai RAAS Blood Products Co., Ltd. (002252.SZ): Canvas Business Model","description":"\u003cp\u003eShanghai RAAS Blood Products Co., Ltd. stands at the forefront of the biotechnology sector, delivering vital solutions through its innovative approach to blood products. With a robust Business Model Canvas that highlights strategic partnerships, cutting-edge technology, and a commitment to quality, this company not only meets the critical needs of healthcare but also sets the stage for future growth and development. Explore the intricacies of their business model below to understand how they are transforming the landscape of life-saving therapies.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai RAAS Blood Products Co., Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eShanghai RAAS Blood Products Co., Ltd. collaborates with various key partners to bolster its position in the blood products market. These partnerships are essential for securing resources, enhancing capabilities, and mitigating potential risks.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Providers\u003c\/h3\u003e\n\u003cp\u003eShanghai RAAS maintains strategic partnerships with numerous healthcare providers, ensuring an efficient distribution of its blood products. In 2022, the company reported a revenue of \u003cstrong\u003eRMB 5.24 billion\u003c\/strong\u003e, with a significant portion derived from sales to hospitals and blood centers. The company has established relationships with over \u003cstrong\u003e1,000 healthcare institutions\u003c\/strong\u003e, aiding in the delivery of its products like intravenous immunoglobulin (IVIG) and albumin.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Agencies\u003c\/h3\u003e\n\u003cp\u003eGovernment partnerships play a critical role in Shanghai RAAS's operations. The company works closely with the National Health Commission of China and local health authorities to comply with regulatory standards. In 2023, government contracts contributed to approximately \u003cstrong\u003e20%\u003c\/strong\u003e of total revenue, translating to around \u003cstrong\u003eRMB 1.05 billion\u003c\/strong\u003e. These collaborations also foster research initiatives aimed at improving blood safety standards and collection processes.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eShanghai RAAS partners with several prominent research institutions to enhance its R\u0026amp;D capabilities. In 2022, the R\u0026amp;D expenditure was around \u003cstrong\u003eRMB 319 million\u003c\/strong\u003e, representing about \u003cstrong\u003e6%\u003c\/strong\u003e of total revenue. Collaborations with institutions such as Shanghai Jiao Tong University focus on developing innovative blood processing techniques and expanding the company’s product pipeline. A notable partnership resulted in the development of a new plasma purification method, improving yield by \u003cstrong\u003e15%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Companies\u003c\/h3\u003e\n\u003cp\u003eStrategic alliances with pharmaceutical companies are crucial for Shanghai RAAS. Such partnerships allow for joint ventures in product development and distribution. For instance, in 2022, the company entered a partnership with a leading pharmaceutical firm to co-develop a recombinant blood product. The expected market share growth from this collaboration is projected to enhance revenues by an estimated \u003cstrong\u003e10%-15%\u003c\/strong\u003e over the next three years. Additionally, the joint venture aims to tap into an estimated market potential of \u003cstrong\u003eRMB 2 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003ePartnership Type\u003c\/th\u003e\n    \u003cth\u003eRevenue Contribution (2022)\u003c\/th\u003e\n    \u003cth\u003eKey Collaborators\u003c\/th\u003e\n    \u003cth\u003eR\u0026amp;D Investment (2022)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n    \u003ctd\u003eRMB 5.24 billion\u003c\/td\u003e\n    \u003ctd\u003e1,000+ Institutions\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGovernment Agencies\u003c\/td\u003e\n    \u003ctd\u003eRMB 1.05 billion\u003c\/td\u003e\n    \u003ctd\u003eNational Health Commission\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003eShanghai Jiao Tong University\u003c\/td\u003e\n    \u003ctd\u003eRMB 319 million\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmaceutical Companies\u003c\/td\u003e\n    \u003ctd\u003eProjecting 10%-15% growth\u003c\/td\u003e\n    \u003ctd\u003eLeading Pharmaceutical Firm\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese key partnerships form the backbone of Shanghai RAAS's operational strategy, allowing the company to leverage external expertise and resources in the competitive landscape of blood products.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai RAAS Blood Products Co., Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eShanghai RAAS Blood Products Co., Ltd. operates within the blood products industry, focusing on several critical activities that drive its value proposition. Below are the key activities that play a significant role in its operational success.\u003c\/p\u003e\n\n\u003ch3\u003ePlasma Collection\u003c\/h3\u003e\n\u003cp\u003eThe plasma collection process is essential for securing raw materials needed for production. As of 2022, Shanghai RAAS has established over \u003cstrong\u003e50 plasma collection stations\u003c\/strong\u003e across China, enabling substantial collection volumes. For instance, the company reported collecting approximately \u003cstrong\u003e1.2 million liters\u003c\/strong\u003e of plasma in the 2022 fiscal year, reflecting a \u003cstrong\u003e15% increase\u003c\/strong\u003e from the previous year.\u003c\/p\u003e\n\n\u003ch3\u003eProduct Manufacturing\u003c\/h3\u003e\n\u003cp\u003eManufacturing is a core activity, where plasma is processed into various products such as albumin, immunoglobulins, and coagulation factor concentrates. In 2022, Shanghai RAAS produced a total of \u003cstrong\u003e1.06 billion RMB\u003c\/strong\u003e (approx. \u003cstrong\u003e155 million USD\u003c\/strong\u003e) in revenue from its product line, with albumin sales contributing to more than \u003cstrong\u003e40%\u003c\/strong\u003e of this figure. The company’s manufacturing facilities have a combined capacity of producing around \u003cstrong\u003e1,200 metric tons\u003c\/strong\u003e of these products annually.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Control\u003c\/h3\u003e\n\u003cp\u003eQuality control ensures that all products meet stringent safety and efficacy standards. Shanghai RAAS invests heavily in quality assurance processes. In the latest annual report, they noted spending approximately \u003cstrong\u003e80 million RMB\u003c\/strong\u003e (approx. \u003cstrong\u003e11.5 million USD\u003c\/strong\u003e) on quality management initiatives. The company adheres to international standards such as \u003cstrong\u003eGMP (Good Manufacturing Practices)\u003c\/strong\u003e, ensuring that over \u003cstrong\u003e95%\u003c\/strong\u003e of its products successfully pass quality tests before reaching the market.\u003c\/p\u003e\n\n\u003ch3\u003eClinical Trials\u003c\/h3\u003e\n\u003cp\u003eClinical trials are vital for developing new products and ensuring their safety and efficacy. As of 2023, Shanghai RAAS has invested over \u003cstrong\u003e100 million RMB\u003c\/strong\u003e (approx. \u003cstrong\u003e14.5 million USD\u003c\/strong\u003e) in ongoing clinical trials. The company is engaged in over \u003cstrong\u003e10 clinical studies\u003c\/strong\u003e focusing on innovative therapies, with three new products projected to enter the market within the next two years.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eActivity\u003c\/th\u003e\n    \u003cth\u003eKey Metrics\u003c\/th\u003e\n    \u003cth\u003eFinancial Investment (2022)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePlasma Collection\u003c\/td\u003e\n    \u003ctd\u003e1.2 million liters collected\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduct Manufacturing\u003c\/td\u003e\n    \u003ctd\u003e1,200 metric tons capacity\u003c\/td\u003e\n    \u003ctd\u003e1.06 billion RMB\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQuality Control\u003c\/td\u003e\n    \u003ctd\u003e95% success rate in quality tests\u003c\/td\u003e\n    \u003ctd\u003e80 million RMB\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eClinical Trials\u003c\/td\u003e\n    \u003ctd\u003e10 ongoing trials\u003c\/td\u003e\n    \u003ctd\u003e100 million RMB\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai RAAS Blood Products Co., Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePlasma collection centers\u003c\/strong\u003e are vital assets for Shanghai RAAS, as they form the backbone of the company's supply chain. As of 2022, the company operated over \u003cstrong\u003e40 plasma collection centers\u003c\/strong\u003e across China. These centers are crucial for sourcing high-quality plasma, which is essential for the production of blood products. The company has invested approximately \u003cstrong\u003eCNY 2 billion\u003c\/strong\u003e to expand its collection capacity and enhance operational efficiency.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSkilled workforce\u003c\/strong\u003e constitutes another significant resource. Shanghai RAAS employs over \u003cstrong\u003e6,000 personnel\u003c\/strong\u003e, including \u003cstrong\u003e1,200 technicians\u003c\/strong\u003e who are trained in the handling and processing of plasma. The workforce is not only essential for operational activities but also plays a key role in ensuring compliance with stringent health and safety regulations. The average annual salary for skilled workers in this industry in China is approximately \u003cstrong\u003eCNY 200,000\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdvanced technology\u003c\/strong\u003e is a critical resource that underpins Shanghai RAAS's production capabilities. The company utilizes state-of-the-art equipment for plasma fractionation and purification processes. Investment in technology has reached about \u003cstrong\u003eCNY 1.5 billion\u003c\/strong\u003e over the past five years, enhancing production efficiency by \u003cstrong\u003e30%\u003c\/strong\u003e and increasing yield rates of plasma-derived products. This technology also supports innovation in product development, enabling the company to expand its product portfolio.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eResource\u003c\/th\u003e\n    \u003cth\u003eDetails\u003c\/th\u003e\n    \u003cth\u003eInvestment Amount (CNY)\u003c\/th\u003e\n    \u003cth\u003eImpact\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePlasma Collection Centers\u003c\/td\u003e\n    \u003ctd\u003eOver 40 operational centers\u003c\/td\u003e\n    \u003ctd\u003e2 billion\u003c\/td\u003e\n    \u003ctd\u003eIncreased plasma sourcing capacity\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSkilled Workforce\u003c\/td\u003e\n    \u003ctd\u003e6,000 employees, 1,200 technicians\u003c\/td\u003e\n    \u003ctd\u003eOngoing training costs\u003c\/td\u003e\n    \u003ctd\u003eEnsures compliance and operational efficacy\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAdvanced Technology\u003c\/td\u003e\n    \u003ctd\u003eState-of-the-art fractionation and purification\u003c\/td\u003e\n    \u003ctd\u003e1.5 billion (5 years)\u003c\/td\u003e\n    \u003ctd\u003e30% efficiency improvement\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory approvals\u003c\/strong\u003e are also a key resource for Shanghai RAAS, as they navigate the complex regulatory landscape of the biopharmaceutical industry. The company holds certifications from the \u003cstrong\u003eChina Food and Drug Administration (CFDA)\u003c\/strong\u003e and has access to international markets, including recent approvals from the \u003cstrong\u003eU.S. FDA\u003c\/strong\u003e for specific plasma products. These approvals allow the company to operate on a global scale, significantly expanding market reach.\u003c\/p\u003e\n\n\u003cp\u003eAs of 2023, it has successfully secured over \u003cstrong\u003e15 international patents\u003c\/strong\u003e related to plasma processing methods and product formulations, highlighting its commitment to innovation and maintaining competitive advantage.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai RAAS Blood Products Co., Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003eShanghai RAAS Blood Products Co., Ltd. specializes in producing high-quality blood products that cater to the medical needs of hospitals and patients. The company's emphasis on quality ensures that its products meet stringent regulatory standards, both domestically and internationally.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-quality blood products\u003c\/h3\u003e\n\u003cp\u003eShanghai RAAS maintains rigorous quality assurance processes, contributing to its reputation as a leader in the blood products market. In 2022, the company reported revenues of approximately \u003cstrong\u003eRMB 10.8 billion\u003c\/strong\u003e, with a gross margin of about \u003cstrong\u003e60%\u003c\/strong\u003e. This success is largely due to their focus on developing high-quality infusion products and coagulation factors.\u003c\/p\u003e\n\n\u003ch3\u003eLife-saving therapies\u003c\/h3\u003e\n\u003cp\u003eThe company's product range includes life-saving therapies such as immunoglobulin, albumin, and clotting factor concentrates. According to the latest reports, the global demand for immunoglobulin therapy has been increasing at a rate of \u003cstrong\u003e10%\u003c\/strong\u003e annually, reflecting a growing recognition of its importance in treating immune deficiencies and autoimmune diseases.\u003c\/p\u003e\n\n\u003ch3\u003eInnovation in treatment\u003c\/h3\u003e\n\u003cp\u003eShanghai RAAS invests significantly in research and development. In the last fiscal year, R\u0026amp;D expenses reached \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e, which is about \u003cstrong\u003e4.6%\u003c\/strong\u003e of total revenue. Recent innovations include advanced purification technologies and new product lines targeting chronic diseases. This commitment to innovation has resulted in several patents, with over \u003cstrong\u003e30 patents\u003c\/strong\u003e filed in the past two years, underscoring their focus on cutting-edge solutions.\u003c\/p\u003e\n\n\u003ch3\u003eReliable supply chain\u003c\/h3\u003e\n\u003cp\u003eThe reliability of Shanghai RAAS’s supply chain is a crucial component of its value proposition. The company has established partnerships with over \u003cstrong\u003e300 hospitals\u003c\/strong\u003e across China, ensuring a consistent delivery of products. In their annual report, they highlighted a \u003cstrong\u003e98%\u003c\/strong\u003e on-time delivery rate, which fosters trust with healthcare providers. Furthermore, the company's inventory turnover ratio stands at \u003cstrong\u003e5.2\u003c\/strong\u003e, indicating efficient management of stock levels to meet market demands.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eKey Value Proposition\u003c\/th\u003e\n    \u003cth\u003eDetails\u003c\/th\u003e\n    \u003cth\u003eFinancial Impact\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHigh-quality blood products\u003c\/td\u003e\n    \u003ctd\u003eRigorous quality assurance process, meeting international standards\u003c\/td\u003e\n    \u003ctd\u003eRevenue: \u003cstrong\u003eRMB 10.8 billion\u003c\/strong\u003e, Gross Margin: \u003cstrong\u003e60%\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLife-saving therapies\u003c\/td\u003e\n    \u003ctd\u003eIncludes immunoglobulin, albumin, and clotting factor concentrates\u003c\/td\u003e\n    \u003ctd\u003eDemand growth: \u003cstrong\u003e10%\u003c\/strong\u003e annually for immunoglobulin\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInnovation in treatment\u003c\/td\u003e\n    \u003ctd\u003eInvestment in R\u0026amp;D with new purification technologies\u003c\/td\u003e\n    \u003ctd\u003eR\u0026amp;D Expenses: \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e, Patents: \u003cstrong\u003e30+\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eReliable supply chain\u003c\/td\u003e\n    \u003ctd\u003ePartnerships with over 300 hospitals and high delivery rates\u003c\/td\u003e\n    \u003ctd\u003eOn-time delivery rate: \u003cstrong\u003e98%\u003c\/strong\u003e, Inventory turnover: \u003cstrong\u003e5.2\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThis combination of high-quality products, life-saving therapies, commitment to innovation, and a reliable supply chain solidifies Shanghai RAAS Blood Products Co., Ltd.'s competitive advantage in the biotechnology sector, ultimately enhancing its value proposition to customers.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai RAAS Blood Products Co., Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eShanghai RAAS Blood Products Co., Ltd. focuses on several key customer relationship strategies to maintain and grow its market presence in the healthcare sector. These include support for healthcare providers, patient education programs, and fostering long-term collaboration.\u003c\/p\u003e\n\n\u003ch3\u003eSupport for Healthcare Providers\u003c\/h3\u003e\n\u003cp\u003eThe company prioritizes building strong relationships with hospitals and clinics, supplying them with high-quality blood products, including human serum albumin and immunoglobulin. As of 2022, Shanghai RAAS reported that it operates over \u003cstrong\u003e200+ partnerships\u003c\/strong\u003e with healthcare facilities across China. The company also provides dedicated customer service teams to assist healthcare providers in the effective use of its products. \u003c\/p\u003e\n\n\u003ch3\u003ePatient Education Programs\u003c\/h3\u003e\n\u003cp\u003eIn an effort to enhance customer engagement, Shanghai RAAS invests in patient education programs aimed at increasing awareness regarding blood products and their applications. In 2022, the company allocated approximately \u003cstrong\u003eRMB 50 million\u003c\/strong\u003e (around \u003cstrong\u003e$7.5 million\u003c\/strong\u003e) for these programs, reaching over \u003cstrong\u003e1 million patients\u003c\/strong\u003e with educational content. These programs include workshops, informational brochures, and online resources that guide patients on the importance of blood products in therapy.\u003c\/p\u003e\n\n\u003ch3\u003eLong-term Collaboration\u003c\/h3\u003e\n\u003cp\u003eShanghai RAAS actively seeks long-term collaboration with both healthcare providers and research institutions. The company is engaged in numerous clinical trials and partnerships aimed at advancing blood product research and development. In 2021, Shanghai RAAS entered into a collaboration with \u003cstrong\u003e12 major hospitals\u003c\/strong\u003e to conduct clinical studies, enhancing its R\u0026amp;D capabilities and broadening its product offerings. The company’s commitment to sustained engagement with these entities is reflected in a \u003cstrong\u003e30% annual increase\u003c\/strong\u003e in collaborative research projects, as reported in their 2022 annual report.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Relationship Aspect\u003c\/th\u003e\n    \u003cth\u003eMetric\u003c\/th\u003e\n    \u003cth\u003eValue\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePartnerships with Healthcare Providers\u003c\/td\u003e\n    \u003ctd\u003eNumber of Partnerships\u003c\/td\u003e\n    \u003ctd\u003e200+\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInvestment in Patient Education\u003c\/td\u003e\n    \u003ctd\u003eAnnual Budget\u003c\/td\u003e\n    \u003ctd\u003eRMB 50 million ($7.5 million)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePatient Reach\u003c\/td\u003e\n    \u003ctd\u003eNumber of Patients Educated\u003c\/td\u003e\n    \u003ctd\u003e1 million+\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCollaborative Research Projects\u003c\/td\u003e\n    \u003ctd\u003eAnnual Growth Rate\u003c\/td\u003e\n    \u003ctd\u003e30%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eClinical Collaboration\u003c\/td\u003e\n    \u003ctd\u003eNumber of Hospitals Collaborated With\u003c\/td\u003e\n    \u003ctd\u003e12\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai RAAS Blood Products Co., Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003ch3\u003eDirect Sales\u003c\/h3\u003e\n\u003cp\u003eShanghai RAAS primarily employs a direct sales approach to reach its customers, which includes hospitals and healthcare systems. In 2022, the company reported that approximately \u003cstrong\u003e60%\u003c\/strong\u003e of its total revenue, which was about \u003cstrong\u003eRMB 14.7 billion\u003c\/strong\u003e, came from direct sales. The direct sales force consists of over \u003cstrong\u003e1,000\u003c\/strong\u003e sales representatives who engage with key healthcare providers across China. The model allows for personalized interactions and a deeper understanding of customer needs.\u003c\/p\u003e\n\n\u003ch3\u003eDistributor Networks\u003c\/h3\u003e\n\u003cp\u003eThe company utilizes a network of distributors to expand its market reach. As of 2023, Shanghai RAAS has partnered with over \u003cstrong\u003e150\u003c\/strong\u003e distributors nationwide. These distributors help the company penetrate regional markets, especially in less accessible areas. In the fiscal year 2022, distributor sales accounted for around \u003cstrong\u003e30%\u003c\/strong\u003e of the total revenue, contributing approximately \u003cstrong\u003eRMB 7.4 billion\u003c\/strong\u003e. This strategy enhances market coverage and allows quick response to local market demands.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platforms\u003c\/h3\u003e\n\u003cp\u003eIn recent years, Shanghai RAAS has increasingly focused on online platforms as a channel for sales and customer engagement. The company has developed a proprietary online ordering system, which has seen a growth of \u003cstrong\u003e40%\u003c\/strong\u003e in user registrations year-over-year. In 2022, online sales generated approximately \u003cstrong\u003eRMB 2.1 billion\u003c\/strong\u003e, representing about \u003cstrong\u003e10%\u003c\/strong\u003e of total revenue. This platform not only facilitates direct transactions but also serves as a communication channel for customer feedback and marketing initiatives.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eChannel Type\u003c\/th\u003e\n    \u003cth\u003eRevenue Contribution (RMB Billion)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n    \u003cth\u003eNumber of Sales Representatives\/Distributors\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDirect Sales\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e14.7\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1,000\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDistributor Networks\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e7.4\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e150\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOnline Platforms\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2.1\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eN\/A\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai RAAS Blood Products Co., Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eShanghai RAAS Blood Products Co., Ltd. serves a diverse range of customer segments, each with distinct needs and requirements. The main customer segments include:\u003c\/p\u003e\n\n\u003ch3\u003eHospitals\u003c\/h3\u003e\n\u003cp\u003eHospitals form a substantial part of Shanghai RAAS's customer base, relying on the company for various blood products such as plasma and coagulation factors. In 2022, the company reported sales of approximately \u003cstrong\u003eRMB 2.5 billion\u003c\/strong\u003e from hospital contracts, showcasing their importance in the revenue stream. The growing demand for high-quality blood products in hospitals is driven by increasing patient needs and advancements in medical procedures.\u003c\/p\u003e\n\n\u003ch3\u003eClinics\u003c\/h3\u003e\n\u003cp\u003eClinics, particularly outpatient facilities, represent another critical customer segment. In 2022, Shanghai RAAS experienced a surge in sales to clinics, reaching around \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e. Clinics utilize blood products for various treatments, including transfusions and diagnostic purposes, which has escalated due to the rising prevalence of chronic diseases.\u003c\/p\u003e\n\n\u003ch3\u003eLaboratories\u003c\/h3\u003e\n\u003cp\u003eLaboratories utilize blood products for research and diagnostic testing. In the last fiscal year, sales to laboratories accounted for approximately \u003cstrong\u003eRMB 800 million\u003c\/strong\u003e. The increasing investment in research and development, particularly in biotechnology, has led to a higher demand for blood-derived products in laboratory settings.\u003c\/p\u003e\n\n\u003ch3\u003eBlood Banks\u003c\/h3\u003e\n\u003cp\u003eBlood banks are crucial in the supply chain for blood products. They ensure adequate blood supply and distribution to hospitals and clinics. In 2022, Shanghai RAAS generated around \u003cstrong\u003eRMB 1.5 billion\u003c\/strong\u003e from blood bank partnerships. The demand for safe and processed blood donations continues to rise, largely due to an increase in surgical procedures and emergency care.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003cthead\u003e\n        \u003ctr\u003e\n            \u003cth\u003eCustomer Segment\u003c\/th\u003e\n            \u003cth\u003e2022 Sales (RMB)\u003c\/th\u003e\n            \u003cth\u003eDescription\u003c\/th\u003e\n        \u003c\/tr\u003e\n    \u003c\/thead\u003e\n    \u003ctbody\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eHospitals\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e2.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003ePrimary source of revenue through the supply of blood products for medical procedures.\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eClinics\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e1.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003eOutpatient facilities using blood products for transfusions and diagnostics.\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eLaboratories\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e800 million\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003eUtilization of blood products for research and diagnostic testing.\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eBlood Banks\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e1.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003eSupply and distribution partnerships critical for ensuring blood availability.\u003c\/td\u003e\n        \u003c\/tr\u003e\n    \u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai RAAS Blood Products Co., Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eThe cost structure of Shanghai RAAS Blood Products Co., Ltd. is integral to its operations, encompassing various expenses that sustain its business model. Below, the key components of this structure are outlined.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Expenses\u003c\/h3\u003e\n\u003cp\u003eManufacturing expenses for Shanghai RAAS primarily include costs related to the production of blood products. In the fiscal year 2022, the company reported total manufacturing expenses amounting to approximately \u003cstrong\u003eRMB 2.1 billion\u003c\/strong\u003e. This figure covers labor costs, raw materials, and utilities consumed during production.\u003c\/p\u003e\n\n\u003ch3\u003eR\u0026amp;D Investments\u003c\/h3\u003e\n\u003cp\u003eResearch and Development (R\u0026amp;D) is crucial for innovation in blood products. In 2022, Shanghai RAAS invested approximately \u003cstrong\u003eRMB 350 million\u003c\/strong\u003e in R\u0026amp;D activities. This investment represents about \u003cstrong\u003e3.5%\u003c\/strong\u003e of the company's total revenue, reflecting a commitment to improving product offerings and technology.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance Costs\u003c\/h3\u003e\n\u003cp\u003eCompliance with industry regulations is essential for operational integrity. Shanghai RAAS incurs significant regulatory compliance costs, which totaled around \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e in 2022. This includes expenses related to certifications, quality assurance, and safety audits required to meet the standards set by health authorities.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Logistics\u003c\/h3\u003e\n\u003cp\u003eDistribution logistics encompass the costs of transporting products to customers and healthcare facilities. In 2022, logistics expenses amounted to approximately \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e. This figure includes transportation, storage, and supply chain management costs, which are vital for timely delivery of blood products.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Component\u003c\/th\u003e\n        \u003cth\u003e2022 Amount (RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Expenses\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e2.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Investments\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e350 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e3.5%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Compliance Costs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e150 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution Logistics\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e200 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eTotal Cost Structure\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e2.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOverall, the cost structure of Shanghai RAAS Blood Products Co., Ltd. is strategically designed to balance operational efficiency with the necessary investments in R\u0026amp;D and regulatory compliance, while effectively managing logistics to ensure product availability and quality. The focus remains on maximizing value while minimizing costs across various segments.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShanghai RAAS Blood Products Co., Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eShanghai RAAS Blood Products Co., Ltd. generates revenue through several distinct streams, primarily revolving around its core business of producing and selling blood products. The three main revenue streams include product sales, licensing agreements, and service fees.\u003c\/p\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eThe majority of Shanghai RAAS's revenues come from the sale of blood products. In 2022, the company reported total revenue of \u003cstrong\u003eRMB 9.975 billion\u003c\/strong\u003e, with blood products accounting for over \u003cstrong\u003e90%\u003c\/strong\u003e of this revenue. Specifically, the sales breakdown includes:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eHuman immunoglobulin: \u003cstrong\u003eRMB 3.6 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFresh frozen plasma: \u003cstrong\u003eRMB 2.1 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFactor VIII: \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOther blood products: \u003cstrong\u003eRMB 3.075 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Type\u003c\/th\u003e\n\u003cth\u003eRevenue (RMB billions)\u003c\/th\u003e\n\u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman immunoglobulin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e36.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFresh frozen plasma\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFactor VIII\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther blood products\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.075\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eLicensing Agreements\u003c\/h3\u003e\n\u003cp\u003eLicensing agreements generate a secondary revenue stream for Shanghai RAAS. The company has entered into various agreements for the production and distribution of specific blood products both domestically and internationally. In 2022, revenues from licensing agreements reached approximately \u003cstrong\u003eRMB 399 million\u003c\/strong\u003e, which represents about \u003cstrong\u003e4%\u003c\/strong\u003e of total revenue.\u003c\/p\u003e\n\n\u003cp\u003eNotable partnerships include licensing for the manufacturing of specific recombinant factors used in hemophilia treatment, contributing significantly to both market share and financial performance.\u003c\/p\u003e\n\n\u003ch3\u003eService Fees\u003c\/h3\u003e\n\u003cp\u003eService fees related to consulting and service contracts with healthcare institutions form another stream of revenue. This segment generated about \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e in 2022, which aligns with approximately \u003cstrong\u003e1.5%\u003c\/strong\u003e of the total revenue. The services offered include:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eTraining programs for healthcare professionals\u003c\/li\u003e\n\u003cli\u003eConsultation on blood management\u003c\/li\u003e\n\u003cli\u003eTechnical support for product usage\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe diversification of revenue streams through product sales, licensing agreements, and service fees reflects Shanghai RAAS's strategic focus on maximizing its offerings within the blood products market and enhancing financial resilience.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45658845511829,"sku":"002252sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/002252sz-business-model-canvas.png?v=1739107418","url":"https:\/\/dcf-model.com\/products\/002252sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}